Headquartered in Santa Monica, CA, Advanced Cell Technology, Inc. is a biotechnology company that develops cellular therapies for the treatment of both rare and common diseases. Using stem cell-based technologies and other proprietary methods in the field of regenerative medicine, ACTC aims to bring patient-specific therapies from the lab to the bedside so that they can help the millions of people affected by disease every day.

The company has three cellular product platforms based on ground breaking stem cell technology: Retinal Pigment Ephithelial (RPE) therapy, Myoblast stem cell therapy and the Hemangioblast (HG) platform. The company is in the process of commercializing its RPE for degenerative retinal disease and has secured two FDA clearances for Phase I/II clinical trials. ACT’s Myoblast stem cell therapy is already Phase-II approved for the treatment of chronic heart failure, advanced cardiac disease, myocardial infarction, and ischemia. Finally, ACT’S Hemangioblast (HG) platform is being developed for the treatment of blood and cardiovascular diseases.

Overseeing ACT’s development is an experienced management team and a world-class scientific team helmed by Interim Chairman and CEO Gary Rabin and Chief Scientific Officer Robert Lanza, M.D., respectively. For more information on the company please visit ww.advancedcell.com.

Let us hear your thoughts: Advanced Cell Technology, Inc. Message Board